EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes

Girmay Desalegn iD, Neeraj Kapoor iD, Lucy Pill-Pepe, Leslie Bautista, Lu Yin, Esther Ndungo iD, Edwin V Oaks, Jeff Fairman, Marcela F Pasetti iD

mSphere · 2023

DOI: 10.1128/msphere.00019-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2023. Verfasst von Girmay Desalegn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Shigella, Shigella Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diarrhea caused by Shigella species results in long-term disability and mortality globally, disproportionally affecting younger children living in poor countries. Although it is treatable by antibiotics, the rapid and widespread emergence of resistant strains and the highly contagious nature of the disease compel the development of preventive tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ShigellaShigella VaccinesAnimalsMiceVaccines, ConjugateSerogroupAntibody FormationLipopolysaccharidesO AntigensPseudomonas aeruginosa Exotoxin A

Stichwörter der Autor:innen

IpaBO-polysaccharide (OPS)Shigellaantibodyconjugate vaccineprotection

Substanzen

Vaccines, ConjugateShigella VaccinesLipopolysaccharidesO AntigensPseudomonas aeruginosa Exotoxin A

Autor:innen und Institutionen

  • Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Vaxcyte, Inc., San Carlos, California, USA.
  • Patuxent Research and Consulting Group, Gambrills, Maryland, USA.

ORCID-Profile: Girmay Desalegn, Neeraj Kapoor, Esther Ndungo, Marcela F Pasetti

Zitieren

APA

Desalegn, G., Kapoor, N., Pill-Pepe, L., Bautista, L., Yin, L., Ndungo, E., Oaks, E. V., Fairman, J., & Pasetti, M. F. (2023). A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes. mSphere. https://doi.org/10.1128/msphere.00019-23

Vancouver

Desalegn G, Kapoor N, Pill-Pepe L, Bautista L, Yin L, Ndungo E, et al. A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes. mSphere. 2023. doi:10.1128/msphere.00019-23

BibTeX
@article{Desalegn2023,
  author = {Desalegn, Girmay and Kapoor, Neeraj and Pill-Pepe, Lucy and Bautista, Leslie and Yin, Lu and Ndungo, Esther and Oaks, Edwin V and Fairman, Jeff and Pasetti, Marcela F},
  title = {A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes},
  journal = {mSphere},
  year = {2023},
  doi = {10.1128/msphere.00019-23}
}
Kostenlos starten →